Mission Pharmacal Patent-Cliff Exposure & CMS Drug Spending Portfolio

Mission Pharmacal (US): 4 reconciled FDA prescription therapies (11.0% 2025 to 2030 cliff risk), $45.2M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies4
2025 to 2030 Patent-Cliff Revenue Exposure11.0%
Primary Portfolio LOE Date2026-01-01
2024 CMS Total Public Spend$45.2M
2024 Medicare Part D Spend$31.0M
2024 Medicaid Spend$14.2M
California HCAI SB 17 Filings0 statutory filings in 2023 to 2026 panel